Medrysone
Clinical data | |
---|---|
Trade names | HMS, Medrocort, others |
Other names | NSC-63278; Hydroxymethylprogesterone; Methylhydroxyprogesterone; Hydroxymesterone; 6α-Methyl-11β-hydroxyprogesterone; 6α-Methyl-11β-hydroxypregn-4-ene-3,20-dione |
AHFS/Drugs.com | Micromedex Detailed Consumer Information |
MedlinePlus | a606003 |
Routes of administration | Eye drops |
ATC code | |
Legal status | |
Legal status |
|
Identifiers | |
| |
CAS Number | |
PubChem CID | |
IUPHAR/BPS | |
DrugBank | |
ChemSpider | |
UNII | |
KEGG | |
ChEMBL | |
CompTox Dashboard (EPA) | |
ECHA InfoCard | 100.018.371 |
Chemical and physical data | |
Formula | C22H32O3 |
Molar mass | 344.495 g·mol−1 |
3D model (JSmol) | |
| |
| |
(what is this?) |
Medrysone (INN, USAN) (brand names HMS, Medrocort, others; former developmental code name NSC-63278), also known as hydroxymethylprogesterone, methylhydroxyprogesterone, or hydroxymesterone, as well as 6α-methyl-11β-hydroxyprogesterone or 6α-methyl-11β-hydroxypregn-4-ene-3,20-dione, is a synthetic glucocorticoid that is or has been used in the treatment of inflammatory eye diseases.[1][2][3] It has been discontinued in the United States.[4] Although it is very similar in structure to progesterone,[5] neither progestogenic nor androgenic activity has been demonstrated for or attributed to medrysone.[6][7][8]
Environmental presence[]
In 2021, medrysone was one of the 12 compounds identified in sludge samples taken from 12 wastewater treatment plants in California that were associated with estrogenic activity in in vitro. [9]
See also[]
References[]
- ^ J. Elks (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 760–. ISBN 978-1-4757-2085-3.
- ^ Index Nominum 2000: International Drug Directory. Taylor & Francis. January 2000. pp. 640–. ISBN 978-3-88763-075-1.
- ^ I.K. Morton; Judith M. Hall (31 October 1999). Concise Dictionary of Pharmacological Agents: Properties and Synonyms. Springer Science & Business Media. pp. 173–. ISBN 978-0-7514-0499-9.
- ^ "HMS - FDA prescribing information, side effects and uses".
- ^ Bedrossian RH, Eriksen SP (1969). "The treatment of ocular inflammation with medrysone". Arch. Ophthalmol. 81 (2): 184–91. doi:10.1001/archopht.1969.00990010186008. PMID 5764682.
- ^ Spaeth GL (1966). "Hydroxymethylprogesterone. An anti-inflammatory steroid without apparent effect on intraocular pressure". Arch. Ophthalmol. 75 (6): 783–7. doi:10.1001/archopht.1966.00970050785014. PMID 5327794.
- ^ Schwartz A, Leopold IH (1971). "Topical anti-inflammatory steroids and intraocular pressure: the place of medrysone". Drugs. 2 (1): 1–4. doi:10.2165/00003495-197102010-00001. PMID 5172545. S2CID 37303359.
- ^ Smolin G (1971). "Medrysone hypersensitivity. Report of a case". Arch. Ophthalmol. 85 (4): 478–9. doi:10.1001/archopht.1971.00990050480015. PMID 5554878.
- ^ Gabrielle P. Black (2021). "Using Estrogenic Activity and Nontargeted Chemical Analysis to Identify Contaminants in Sewage Sludge". Environmental Science & Technology. 55 (10): 6729–6739. Bibcode:2021EnST...55.6729B. doi:10.1021/acs.est.0c07846. ISSN 0013-936X. PMC 8378343. PMID 33909413.
- Secondary alcohols
- Diketones
- Glucocorticoids
- Pregnanes
- Steroid stubs